Item 5.07 Submission of Matters to a Vote of Security Holders.
A total of 33,923,148 shares of common stock of Collegium Pharmaceutical, Inc. (the "Company") were entitled to vote as of March 31, 2022, the record date for the Annual Meeting, of which 31,262,511 were present in person or by proxy at the Annual Meeting. The following is a summary of the final voting results for each matter presented to shareholders.
Each of Rita Balice-Gordon, Garen Bohlin, John Fallon, John Freund, Neil F. McFarlane and Gwen Melincoff was re-elected by the Company's shareholders as Directors to hold office until the 2023 Annual Meeting of Shareholders.
Approval of, on an advisory basis, the compensation of the Company's named executive officers.
On an advisory basis, the Company's shareholders approved the compensation of the Company's named executive officers.
Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.
Proposal 3 was approved by the Company's shareholders.
© Edgar Online, source Glimpses